Incidence of second and higher order smoking-related primary cancers following lung cancer: a population-based cohort study

Matthew E Barclay, Georgios Lyratzopoulos, Fiona M Walter, Sarah Jefferies, Michael D Peake, Robert C Rintoul, Matthew E Barclay, Georgios Lyratzopoulos, Fiona M Walter, Sarah Jefferies, Michael D Peake, Robert C Rintoul

Abstract

Background: Lung cancer 5-year survival has doubled over 15 years. Although the risk of second primary cancer is recognised, quantification over time is lacking. We describe the incidence of second and higher order smoking-related primary cancers in lung cancer survivors, identifying high-incidence groups and how incidence changes over time from first diagnosis.

Methods: Data on smoking-related primary cancers (lung, laryngeal, head and neck, oesophageal squamous cell carcinoma and bladder) diagnosed in England between 2000 and 2014 were obtained from Public Health England National Cancer Registration and Analysis Service. We calculated absolute incidence rates and standardised incidence rate ratios, both overall and for various subgroups of second primary cancer for up to 10 years from the initial diagnosis of lung cancer, using Poisson regression.

Results: Elevated incidence of smoking-related second primary cancer persists for at least 10 years from first lung cancer diagnosis with those aged 50 and 79 at first diagnosis at particularly high risk. The most frequent type of second malignancy was lung cancer although the highest standardised incidence rate ratios were for oesophageal squamous cell carcinoma (2.4) and laryngeal cancers (2.8) and consistently higher in women than in men. Over the last decade, the incidence of second primary lung cancer has doubled.

Conclusion: Lung cancer survivors have increased the incidence of subsequent lung, laryngeal, head and neck and oesophageal squamous cell carcinoma for at least a decade from the first diagnosis. Consideration should be given to increasing routine follow-up from 5 years to 10 years for those at highest risk, alongside surveillance for other smoking-related cancers.

Keywords: clinical epidemiology; lung cancer; non-small cell lung cancer.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Absolute incidence of second and higher order smoking-related primary cancers after lung diagnosis up to 10 years follow-up, by sex and age group.
Figure 2
Figure 2
Standardised incidence rate ratios for second and higher order smoking-related primary cancers after lung diagnosis up to 10 years follow-up, by sex and age group. Results for the 30–49 age group are imprecise due to the small number of cancers expected in this group.
Figure 3
Figure 3
Standardised incidence rate ratios for second and higher order smoking-related primary cancers after lung diagnosis up to 10 years follow-up, by site of second primary cancer. SCC, squamous cell carcinoma.
Figure 4
Figure 4
Incidence rate ratio for incidence of second primary cancers between 6 and 60 months after first primary lung cancer diagnosis in patients diagnosed with first primary lung cancer in 2005–2009 and 2010–2014 compared with 2000–2004, split into lung cancer, bladder cancer and OSCC, laryngeal, head and neck cancer. Note that most patients diagnosed in 2010–2014 have less than 5 years follow-up in our analysis dataset. OSCC,  oesophageal squamous cell carcinomas.

References

    1. Walters S, Benitez-Majano S, Muller P, et al. . Is England closing the international gap in cancer survival? Br J Cancer 2015;113:848–60. 10.1038/bjc.2015.265
    1. De Angelis R, Sant M, Coleman MP, et al. . Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5-a population-based study. Lancet Oncol 2014;15:23–34. 10.1016/S1470-2045(13)70546-1
    1. Tabuchi T, Ito Y, Ioka A, et al. . Incidence of metachronous second primary cancers in Osaka, Japan: update of analyses using population-based cancer registry data. Cancer Sci 2012;103:1111–20. 10.1111/j.1349-7006.2012.02254.x
    1. Jégu J, Colonna M, Daubisse-Marliac L, et al. . The effect of patient characteristics on second primary cancer risk in France. BMC Cancer 2014;14:94 10.1186/1471-2407-14-94
    1. Youlden DR, Baade PD. The relative risk of second primary cancers in Queensland, Australia: a retrospective cohort study. BMC Cancer 2011;11:83 10.1186/1471-2407-11-83
    1. Surapaneni R, Singh P, Rajagopalan K, et al. . Stage I lung cancer survivorship: risk of second malignancies and need for individualized care plan. J Thorac Oncol 2012;7:1252–6. 10.1097/JTO.0b013e3182582a79
    1. Siegel RL, Jacobs EJ, Newton CC, et al. . Deaths due to cigarette smoking for 12 smoking-related cancers in the United States. JAMA Intern Med 2015;175:1574–6. 10.1001/jamainternmed.2015.2398
    1. Møller H, Richards S, Hanchett N, et al. . Completeness of case ascertainment and survival time error in English cancer registries: impact on 1-year survival estimates. Br J Cancer 2011;105:170–6. 10.1038/bjc.2011.168
    1. Working Group Report. International rules for multiple primary cancers (ICD-0 third edition). Eur J Cancer Prev 2005;14:307–8. 10.1097/00008469-200508000-00002
    1. Department for Communities and Local Government. English indices of deprivation 2015. 2015.
    1. Office for National Statistics. Lower super output area mid-year population estimates. 2015. (Accessed 07 Mar 2016).
    1. Bennette C, Vickers A. Against quantiles: categorization of continuous variables in epidemiologic research, and its discontents. BMC Med Res Methodol 2012;12:21 10.1186/1471-2288-12-21
    1. Harrel FE. Regression modelling strategies: with applications to linear models, logistic regression, and survival analysis. New York: Springer, 2015.
    1. Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr 1974;19:716–23. 10.1109/TAC.1974.1100705
    1. Coyte A, Morrison DS, McLoone P. Second primary cancer risk - the impact of applying different definitions of multiple primaries: results from a retrospective population-based cancer registry study. BMC Cancer 2014;14:272–72. 10.1186/1471-2407-14-272
    1. Su VY, Liu CJ, Chen YM, et al. . Risk of second primary malignancies in lung cancer survivors - The influence of different treatments. Target Oncol 2017;12:219–27. 10.1007/s11523-016-0459-0
    1. Abdel-Rahman O, Cheung WY. Subsequent thoracic cancers among patients diagnosed with lung cancer: a SEER database analysis. Curr Med Res Opin 2017;33:2009–17. 10.1080/03007995.2017.1333953
    1. Thakur MK, Ruterbusch JJ, Schwartz AG, et al. . Risk of second lung cancer in patients with previously treated lung cancer: analysis of Surveillance, Epidemiology, and End Results (SEER) Data. J Thorac Oncol 2018;13:46–53. 10.1016/j.jtho.2017.09.1964
    1. Han SS, Rivera GA, Tammemägi MC, et al. . Risk stratification for second primary lung cancer. J Clin Oncol 2017;35:2893–9. 10.1200/JCO.2017.72.4203
    1. Tabuchi T, Ito Y, Ioka A, et al. . Tobacco smoking and the risk of subsequent primary cancer among cancer survivors: a retrospective cohort study. Ann Oncol 2013;24:2699–704. 10.1093/annonc/mdt279
    1. Donin N, Filson C, Drakaki A, et al. . Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008. Cancer 2016;122:3075–86. 10.1002/cncr.30164
    1. Warren GW, Sobus S, Gritz ER. The biological and clinical effects of smoking by patients with cancer and strategies to implement evidence-based tobacco cessation support. Lancet Oncol 2014;15:e568–80. 10.1016/S1470-2045(14)70266-9

Source: PubMed

3
Prenumerera